BACK TO ALL REFERENCES
ReTreatPD: Disease-modifying therapies for Parkinson’s disease
The ReTreatPD project by Herantis Pharma Plc will focus on preparations towards a Phase 2 clinical study with HER-096 in conjunction with Parkinson’s disease (PD).
€2.5 m
in funding
2
years
Key numbers
About the project
Herantis is advancing their biomarker development with this funding, as recent developments have shown that biomarkers play an increasingly important role in clinical trial design for CNS drug candidates. The current dopamine substitution treatments alleviate some of the symptoms, however, there is no cure for PD nor any disease-modifying therapieshas developed a new pharmaceutical HER-096, able to affect PD pathology and potential to revolutionise the treatment of PD, alleviating the huge burden it now causes patients and healthcare.
Impact of the project:
The potential of the project outcome is to slow down or even stop Parkinson's disease progression, which the currently available treatments cannot do.
Funding instrument European Innovation Council (EIC)
Spinverse’s role
Spinverse team was guiding Herantis Pharma Plc on their path to the successful outcome in the competitive funding application process by providing support in project planning, application writing and pitching.
The biggest benefit in working with Spinverse was that they are very familiar with the application process and advised us on how to formulate our project to meet EIC Accelerator’s expectations and requirements. Spinverse also challenged us to focus on the right things in our project, which for its part led to the successful outcome..
Supporting the UN Sustainable Development Goals
We share what we learn
Read our latest news on our references
